US patient-centric data analytics company, Trayt Technologies (formerly Ava Health), has developed an app to help improve the diagnosis, treatment and quality of life for patients with autism, ADHD and other neurodevelopmental and brain disorders.
Founder and CEO of Trayt, Malekeh Amini, developed the idea for the app after her son was diagnosed with neurodevelopmental disorders in 2010. Amini’s son exhibited several overlapping neurological and non-neurological symptoms that physicians and therapists ended up treating as independent conditions, which didn’t lead to any positive results.
Therefore in 2014, in collaboration with Professor Emeritus of Psychiatry at Stanford University and Clinical Professor of Psychiatry at UC Riverside (California), Dr Carl Feinstein, Amini formed Ava Health to better understand the symptoms of neurodevelopmental disorders, how they are connected and how best to ensure personalised treatment plans and quality of life for patients.
Following their recent rebrand as Trayt, the company launched their mHealth app, for both iOS and Android devices, though which parents, caregivers and doctors can collect and analyse health data of patient’s with brain-based disorders to ensure the relevant treatment is given and to monitor outcomes.
“We are all different, yet the conventions of healthcare often mean that we are treated the same. Trayt unearths what’s unique about each of us by tracking and aggregating observations from parents, other caregivers and physicians, and then analysing this data to identify specific underlying diseases, reveal causal relationships between two or more chronic conditions, and inform the best treatment for that person,” said Amini.
“We’ve assembled a team of experts, and partnered with leading clinics to optimise our analytic models. Over larger data sets, we hope to predict how a patient will react to a treatment before it’s even prescribed,” continued Amini.
“As a physician, I have experienced the frustration of parents with the fragmentation of care they receive from a variety of specialists, the failure to integrate the medical with the behavioural aspects of their children’s problems, and the frequent failure of care providers to target for treatment the symptoms that parents identify as the most urgent,” said Dr Feinstein.
“Parents should be in the driver’s seat in championing the personalised care of their children. It is our job to support them in doing this, with all the means at our disposal,” continued Dr Feinstein.
Through the Trayt app parents and caregivers can measure a patient’s symptoms in terms of intensity, frequency and duration. Trayt then analyses the data and provides progress reports and personalised, actionable information through a dashboard.
According to the company, Trayt’s analytic engine delivers patient insights and recommendations that provide a daily roadmap to improve long-term health, and keeps physicians and therapists up to date on the patient’s progress.
At the moment the app is only available for parent volunteers in the US who wish to participate in a pilot study to improve the quality of life of their children.
“The parents of children with neurodevelopmental disorders are an invaluable source of information that hasn’t been listened to nearly enough. Collecting patient-reported outcomes is crucial to improving treatment,” said Amini.
“Not only will it lead to improved outcomes in the present, it will also greatly facilitate coordination of care between parents, doctors and other care providers. In the future, the outcomes data collected from the on-going treatment of large numbers of these patients will lead to an improved evidence base for all, based on the science of bioinformatics,” concluded Amini.